用户名:  密码:   
网站首页即时通讯活动公告最新消息科技前沿学人动向两岸三地人在海外历届活动关于我们联系我们申请加入
栏目导航 — 美国华裔教授专家网科技动向生物医学
关键字  范围   
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
2020/8/8 18:53:49 | 浏览:1728 | 评论:0
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
     
TOP STORIES
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
BIOPROCESSING
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
CANCER & DISEASE RESEARCH Sponsored by Beckman Coulter
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
CELL BIOLOGY
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
DRUG DISCOVERY & DEVELOPMENT
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
GENOMICS Sponsored by Nvidia
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
IMMUNOLOGY Sponsored by Beckman Coulter
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
PROTEOMICS
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
  SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesInsights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesCommunities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
 
SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapiesRewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
 
 

 

Dear Science Advisory Board Member,

As more molecular coronavirus research becomes published, we are getting a better view of the SARS-CoV-2 virus and its pathogenicity. Particularly, how the virus leverages nonstructural proteins to undermine host immune defenses and how blocking these proteins may effectively stop the virus in its tracks. More detailed molecu lar views of these accessory proteins will guide structure-based drug design and bring us one step closer to beating this pandemic.

As an example, researchers from the U.S. National Institutes of Health(NIH)and other academic institutions in the U.S. described how they rapidly developed a SARS-CoV-2 vaccine candidate based on the genetic sequences of the virus and previous work with messenger RNA(mRNA)vaccine delivery systems.

This vaccine candidate, mRNA-1273, is being jointly developed by the NIH and Moderna and is part of the agency's large-scale clinical trial protocol, Accelerating COVID-19 Therapeutic Interventions and Vaccines(ACTIV). The program includes both vaccines and treatments, and the NIH announced that it has launched phase II studies for the investigational monoclonal antibody Ly-CoV555 developed by Eli Lilly and AbCellera.

Other contenders, like Johnson & Johnson's Ad-26 and Inovio's Ino-4800, are posting positive preclinical results and their developers expect to begin late-stage clinical testing soon. Funding through the U.S. government's Operation Warp Speed program is still being allocated to new vaccine candidates, such as a recombinant protein-based vaccine being developed by Sanofi and GlaxoSmithKline.

Aside from COVID-19 developments, several notable advances in immunotherapies and gene therapies were announced this week. Bio-Rad won an important patent infringement appeal over 10X Genomics, which gives it an edge in the gene expression products market. Meanwhile, Omega Therapeutics is advancing its epigenomic programming platform in clinical trials, and SAB Therapeutics has begun testing a seasonal flu immunotherapy.

Stay healthy and safe.

SARS-CoV-2 structure informs clinical trials | Progress in gene therapies, immunotherapies
Samantha Black, PhD
The Science Advisory Board Editor
editor@scienceboard.net
相关栏目:『生物医学
长期吃米和长期吃面的人,谁的心血管更健康? 2025-07-03 [49]
中国,为什么不吸烟者中也有很多肺癌患者? | 商周专栏 2025-07-01 [74]
ASCO 2025 特辑|全球专家对话:从临床试验到肾癌治疗新突破 2025-07-01 [80]
Science:大语言模型模拟5亿年进化,开启蛋白质设计新纪元 2025-06-12 [687]
躺着也能治病?被你嫌弃的“侧卧”或能击退睡眠呼吸暂停患者的深夜危机 2025-06-06 [729]
体内CAR-T的发展得益于mRNA技术的成熟 2025-06-06 [674]
鼻滴干细胞外泌体,改善焦虑、抑郁行为!指标减少近50% 2025-06-06 [880]
脑力工作者最好的休息方式:不是睡觉 2025-06-03 [949]
Tempus AI:AI 医疗的一个数据引擎? 2025-06-05 [683]
50岁以下患癌群体中女性占三分之二,为什么女性患癌者越来越多? 2025-05-28 [870]
相关栏目更多文章
最新图文:
:引力波天文台或有助搜寻暗物质粒子 :Sail Through the Mist - SoCal Innovation Forum 2019(10/5) 游天龙:《唐人街》是如何炼成的:UCLA社会学教授周敏的学术之路 :“为什么海外华人那么爱国,但是让他回国却不愿意?...“ :学术出版巨头Elsevier 彻查433名审稿人“强迫引用”黑幕 :中国336个国家重点实验室布局 :中澳政府联合出手打击洗钱和逃税漏税 大量中国居民海外账户遭冻结 :摄影师苏唐诗与寂寞百年的故宫对话6年,3万张照片美伦美奂
更多最新图文
更多《即时通讯》>>
 
打印本文章
 
您的名字:
电子邮件:
留言内容:
注意: 留言内容不要超过4000字,否则会被截断。
未 审 核:  是
  
关于我们联系我们申请加入后台管理设为主页加入收藏
美国华裔教授专家网版权所有,谢绝拷贝。如欲选登或发表,请与美国华裔教授专家网联系。
Copyright © 2025 ScholarsUpdate.com. All Rights Reserved.